TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07252440: A Prospective, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

Sponsor: Shanghai Auzone Biological Technology Co., Ltd. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT07252440 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07252440 Rescue Dossier →